About ADC Therapeutics S.A.
https://www.adctherapeutics.comADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors.
CEO
Ameet Mallik
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 35
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Guggenheim
Buy
RBC Capital
Outperform
Cantor Fitzgerald
Overweight
Stephens & Co.
Overweight
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
REDMILE GROUP, LLC
Shares:15.67M
Value:$58.12M
POINT72 ASSET MANAGEMENT, L.P.
Shares:8.14M
Value:$30.18M
PROSIGHT MANAGEMENT, LP
Shares:7.47M
Value:$27.72M
Summary
Showing Top 3 of 112
About ADC Therapeutics S.A.
https://www.adctherapeutics.comADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $16.43M ▼ | $46.19M ▼ | $-40.97M ▲ | -249.38% ▲ | $-0.3 ▲ | $-27.45M ▲ |
| Q2-2025 | $18.84M ▼ | $62.15M ▲ | $-56.65M ▼ | -300.68% ▼ | $-0.5 ▼ | $-41.55M ▼ |
| Q1-2025 | $23.03M ▲ | $49.44M ▲ | $-38.6M ▼ | -167.59% ▲ | $-0.36 ▼ | $-25.69M ▼ |
| Q4-2024 | $16.91M ▼ | $47.98M ▼ | $-30.73M ▲ | -181.71% ▲ | $-0.29 ▲ | $-18.83M ▲ |
| Q3-2024 | $18.46M | $53.18M | $-43.97M | -238.13% | $-0.42 | $-29.7M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $234.74M ▼ | $289.76M ▼ | $527.94M ▲ | $-238.18M ▼ |
| Q2-2025 | $264.56M ▲ | $321.56M ▲ | $520.75M ▲ | $-199.18M ▲ |
| Q1-2025 | $194.7M ▼ | $272.54M ▼ | $510.76M ▼ | $-238.22M ▼ |
| Q4-2024 | $250.87M ▼ | $321.98M ▼ | $524.62M ▲ | $-202.64M ▼ |
| Q3-2024 | $274.27M | $349.08M | $521.02M | $-171.95M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-40.97M ▲ | $-29.63M ▼ | $0 | $-198K ▼ | $-29.82M ▼ | $-29.63M ▼ |
| Q2-2025 | $-56.65M ▼ | $-24.09M ▲ | $0 ▲ | $93.78M ▲ | $69.86M ▲ | $-24.09M ▲ |
| Q1-2025 | $-38.6M ▼ | $-56.33M ▼ | $-264K ▼ | $271K ▲ | $-56.17M ▼ | $-56.6M ▼ |
| Q4-2024 | $-30.73M ▲ | $-21.85M ▲ | $-90K ▲ | $-1.12M ▼ | $-23.41M ▲ | $-21.94M ▲ |
| Q3-2024 | $-43.97M | $-25.04M | $-216K | $-879K | $-25.85M | $-25.26M |
Revenue by Products
| Product | Q4-2024 | Q3-2025 | Q2-2025 | Q1-2025 |
|---|---|---|---|---|
 License Revenues | $0 ▲ | $0 ▲ | $0 ▲ | $10.00M ▲ |
 Product | $30.00M ▲ | $20.00M ▼ | $20.00M ▲ | $20.00M ▲ |
 Royalty Revenue | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
Revenue by Geography
| Region | Q4-2024 | Q2-2025 | Q1-2025 | Q3-2025 |
|---|---|---|---|---|
 EMEA | $0 ▲ | $0 ▲ | $10.00M ▲ | $0 ▼ |
 UNITED STATES | $30.00M ▲ | $20.00M ▼ | $20.00M ▲ | $20.00M ▲ |
CEO
Ameet Mallik
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 35
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Guggenheim
Buy
RBC Capital
Outperform
Cantor Fitzgerald
Overweight
Stephens & Co.
Overweight
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
REDMILE GROUP, LLC
Shares:15.67M
Value:$58.12M
POINT72 ASSET MANAGEMENT, L.P.
Shares:8.14M
Value:$30.18M
PROSIGHT MANAGEMENT, LP
Shares:7.47M
Value:$27.72M
Summary
Showing Top 3 of 112